Core Viewpoint - OptimizeRx Corp. (OPRX) shares experienced a 5.9% increase, closing at $7.18, following a significant trading volume, contrasting with an 11.3% decline over the past month [1] Group 1: Market Opportunity and Business Model - The rise in share price is linked to an expanding market opportunity and a robust business model, with increasing demand for OPRX's Dynamic Audience Activation Platform (DAAP) [2] - The DAAP solution provides predictive and secure marketing, connecting patients, healthcare professionals (HCPs), and life sciences through a strong network [2] Group 2: Client Engagement and Customer Acquisition - OPRX maintains strong engagement with existing clients while acquiring new customers, particularly in mid-tier and long-tail life science companies, which management views as an attractive segment [3] Group 3: AI Integration and Cost Management - The company positions AI as a beneficial factor, suggesting it will enhance marketing budgets, which are typically 50% allocated to content creation, allowing for reallocation towards marketing execution and audience reach [4] - OPRX benefits from a fixed cost base and a scalable operating model, with EBITDA improving due to cost discipline measures following the Medicx acquisition [4] Group 4: Financial Guidance and Share Repurchase - Management projects 2026 revenue between $109 million and $114 million, with adjusted EBITDA expected to be in the range of $21–$25 million [5] - A share repurchase plan of $10 million is also in place [5] Group 5: Earnings Expectations - The company is anticipated to report quarterly earnings of $0.02 per share, reflecting a year-over-year decline of 75%, with revenues expected at $19.34 million, down 11.8% from the previous year [6] - The consensus EPS estimate has been revised 136.4% lower in the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [7] Group 6: Industry Context - OPRX holds a Zacks Rank of 1 (Strong Buy), indicating positive market sentiment, while ACI Worldwide, a peer in the same industry, has a Zacks Rank of 4 (Sell) [7][8]

Core Insights - OptimizeRx Corp. reported strong financial results for Q4 2025, with revenue of $32.2 million and adjusted EBITDA of $12.0 million, exceeding both consensus and internal expectations [4][8] - The company achieved a record full-year revenue of $109.4 million, reflecting a 19% increase from $92.1 million in 2024, and demonstrated a profitable growth model with a margin exceeding 20% [4][8] - The company is focused on becoming a sustainable "Rule of 40" company, indicating a balance between growth and profitability [4] Financial Highlights - Q4 gross profit increased by 9% year-over-year to $24.1 million, up from $22.0 million in Q4 2024 [7][8] - Q4 net income reached $5.0 million, or $0.26 per diluted share, compared to a net loss of $(0.1) million in the same period of 2024 [8] - Full-year adjusted EBITDA totaled $24.3 million, compared to $11.7 million in the previous year [8] Guidance and Future Outlook - The company updated its 2026 revenue guidance to between $109 million and $114 million, with adjusted EBITDA expected to be between $21 million and $25 million [10] - The company is experiencing increased market volatility due to uncertainty surrounding Most Favored Nation (MFN) pricing, which may lead to some near-term headwinds [5] Share Repurchase Program - OptimizeRx's Board has authorized a $10 million share repurchase program, effective March 12, 2026, to be executed based on market conditions [11] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturers decreased to $2,838 in 2025 from $2,976 in 2024 [9] - Net revenue retention was 116% in 2025, down from 121% in 2024 [9] - Revenue per average full-time employee increased to $839 in 2025 from $701 in 2024 [9]

Core Insights - OptimizeRx Corp. reported strong financial results for Q4 2025, with revenue of $32.2 million and adjusted EBITDA of $12.0 million, exceeding both consensus and internal expectations [3] - For the full year 2025, the company achieved record revenue of $109.4 million, a 19% increase from $92.1 million in 2024, and adjusted EBITDA of $24.3 million, reflecting a margin of over 20% [3][7] - The company aims to maintain its status as a "Rule of 40" company, indicating a focus on sustainable growth and profitability [3] Financial Performance - Q4 2025 revenue was $32.2 million, consistent with Q4 2024's $32.3 million [6][7] - Q4 gross profit increased by 9% year-over-year to $24.1 million [6][7] - Q4 net income reached $5.0 million, compared to a net loss of $(0.1) million in Q4 2024 [7] - Full year 2025 net income totaled $5.1 million, a significant recovery from a net loss of $(20.1) million in 2024 [7] - Cash and cash equivalents increased to $23.4 million as of December 31, 2025, up from $13.4 million a year earlier [7] Guidance and Outlook - The company updated its 2026 revenue guidance to between $109 million and $114 million, with adjusted EBITDA expected to be between $21 million and $25 million [6][9] - Despite increased market volatility and customer caution regarding discretionary spending, the company remains confident in underlying demand trends [4][5] Share Repurchase Program - OptimizeRx's board authorized a share repurchase program for up to $10 million of the company's outstanding common stock, effective March 12, 2026 [10] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturers was $2,838, down from $2,976 in 2024 [8] - Net revenue retention was 116%, slightly down from 121% in 2024 [8] - Revenue per average full-time employee increased to $839 from $701 in 2024 [8]

Core Viewpoint - OptimizeRx Corp. is set to discuss its fourth quarter financial results for the period ending December 31, 2025, during a conference call on March 5, 2026, at 4:30 p.m. Eastern Time [1]. Group 1: Conference Call Details - The conference call will be hosted by OptimizeRx management and will include a question-and-answer session [2]. - Participants can join the call via toll-free and international numbers, with a specific conference ID provided [2]. - A replay of the call will be available for 12 months on the OptimizeRx investor relations website [3]. Group 2: Company Overview - OptimizeRx is a leading healthcare technology company that enhances connections between life sciences brands, healthcare professionals (HCPs), and patients [4]. - The company utilizes AI-driven tools, such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® audiences, to facilitate timely and relevant engagement [4]. - OptimizeRx emphasizes privacy-safe, patient-centric technology to ensure impactful interactions that deliver therapies to patients effectively [5].

Core Insights - OptimizeRx Corp has announced a data collaboration with Experian to enhance audience measurement for life science marketers, providing a more accurate and transparent view of campaign engagement and effectiveness [1][3] Group 1: Collaboration and Integration - The integration of OptimizeRx's Micro-Neighborhood audience data with Experian's identity graph allows for seamless onboarding and audience activation, improving the ability to reach and measure consumer audiences at scale [1][3] - This collaboration aims to close the visibility gap in direct-to-consumer marketing by providing a reliable methodology for life sciences brands and healthcare marketing agencies [2][3] Group 2: Audience Measurement and Quality - The partnership addresses fragmentation in identity resolution, which has historically limited the visibility of direct-to-consumer campaigns, preventing accurate measurement of marketing impact [2][5] - By improving audience mapping, the collaboration is expected to reduce audience loss during onboarding, thereby increasing total media reach and enhancing audience quality [6][3] Group 3: Micro-Neighborhood Audiences - OptimizeRx's Micro-Neighborhood audiences are created using real-world, privacy-safe clinical and consumer data, allowing for highly precise segmentation at the ZIP+9 level across over 35 million U.S. micro-neighborhoods [4][7] - These audiences are designed to be portable across major media channels, facilitating omnichannel direct-to-consumer advertising for life science marketers [7][8] Group 4: Company Overview - OptimizeRx is a leading healthcare technology company focused on redefining connections between life science brands and patients, utilizing AI-driven tools to enhance engagement [8][9] - Experian is a global data and technology company that provides insights and solutions across various markets, including healthcare, to improve marketing effectiveness and consumer engagement [10][11]

Core Viewpoint - OptimizeRx Corp. has announced four new partner agreements that significantly enhance its point-of-care (POC) network, strengthen its competitive position, and expand its National Provider Identifier (NPI) reach [1][2]. Partnership Agreements - The new agreements include partnerships with an eRx platform and a health systems access partner, which together increase OptimizeRx's unique NPI reach by 37% [3][9]. - The eRx platform was previously part of a competitive network, while the health systems access partner allows OptimizeRx to engage healthcare professionals (HCPs) at critical points in patient care [3][9]. Strategic Footprint Expansion - These partnerships reinforce OptimizeRx's leadership in the POC marketing landscape and secure exclusive access to premium inventory, enhancing visibility into future channel revenue [4][10]. - Renewals with top-performing EHR and eRx platforms further solidify these relationships, based on historical strong utilization and high returns on investment (ROIs) for life sciences brands [4][10]. Growth Positioning - The CEO of OptimizeRx emphasized that deepening relationships with high-value partners and gaining access to large-scale platforms positions the company for sustained, profitable growth [5]. - The company aims to enhance its clients' ability to reach a larger audience of relevant providers, driving brand awareness and conversion [5][10]. Technology and Innovation - OptimizeRx utilizes innovative, AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to facilitate timely and relevant engagement between life sciences brands and healthcare providers [6]. - The company's commitment to privacy-safe, patient-centric technology aims to deliver impactful interactions that improve patient outcomes [7].

Core Insights - OptimizeRx Corp. will hold a conference call on November 6, 2025, to discuss its third-quarter financial results for the period ending September 30, 2025 [1][2] - The call will include a question-and-answer session and will be accessible via toll-free and international numbers [2] - A replay of the call will be available for 12 months on the company's investor relations website [3] Company Overview - OptimizeRx is a leading healthcare technology company focused on enhancing connections between life science brands, patients, and healthcare providers [4] - The company utilizes AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to facilitate timely and relevant engagement [4] - OptimizeRx emphasizes privacy-safe, patient-centric technology to ensure impactful interactions that deliver therapies to patients effectively [5] - The company is headquartered in Waltham, Massachusetts, and collaborates with major pharmaceutical and life sciences companies to improve healthcare outcomes [5]

Core Insights - OptimizeRx Corp. will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference on September 11, 2025, in New York, NY [1] - The company is a leading provider of healthcare technology solutions that help life sciences companies engage healthcare professionals and patients [1][3] Company Overview - OptimizeRx utilizes AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to enhance engagement strategies [3] - The company focuses on creating synchronized marketing solutions that facilitate faster treatment decisions and improve patient outcomes [3] - OptimizeRx is committed to privacy-safe, patient-centric technology, ensuring impactful interactions that deliver therapies to the right patients at the right time [4] - The company partners with leading pharmaceutical and life sciences companies to transform the healthcare landscape [4]

Core Insights - OptimizeRx Corp. announced organizational updates and leadership advancements aimed at accelerating its Rule of 40 strategy, which focuses on balancing sustained growth with increased profitability [1][2] Leadership Advancements - Ed Stelmakh has been appointed Chief Financial & Strategic Officer (CFSO), expanding his role to include corporate strategy alongside financial leadership, emphasizing profitable growth and shareholder value creation [3] - Theresa Greco continues as Chief Commercial Officer (CCO), overseeing the commercial team and focusing on sustainable revenue growth through a transition to a recurring revenue model [4] - Marion Odence-Ford has been named Chief Legal & Administrative Officer (CLAO), expanding her role to include oversight of key administrative functions and ensuring alignment between legal and strategic initiatives [5] - Doug Besch remains Chief Product & Technology Officer (CPTO), focusing on product enhancements and platform optimization to capture market share in pharma's commercial spend [6] - Brendan Merrell has been appointed Chief Operating Officer (COO), emphasizing operational excellence and driving operating leverage across the company [7] - Andy D'Silva has been promoted to Chief Business Officer (CBO), focusing on strategic planning and championing Rule of 40 strategies to accelerate growth initiatives [8]

Core Viewpoint - OptimizeRx Corp. is set to discuss its second quarter financial results for the period ending June 30, 2025, during a conference call scheduled for August 7, 2025 [1][2]. Company Overview - OptimizeRx is a leading healthcare technology company that focuses on connecting life science brands with patients and healthcare providers through innovative solutions [4]. - The company utilizes AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to enhance engagement and improve patient outcomes [4]. - OptimizeRx is committed to privacy-safe, patient-centric technology, ensuring impactful interactions that deliver therapies to the right patients at the right time [5]. Conference Call Details - The conference call will take place on August 7, 2025, at 4:30 p.m. Eastern Time, with a question-and-answer session following the management's presentation [2]. - Participants can join the call via toll-free and international numbers, and a webcast will also be available [2]. - A replay of the call will be accessible for 12 months on the company's investor relations website [3].